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Abstract
Purpose—Congenital hypogonadotropic hypogonadism (CHH) and split hand/foot malformation 
(SHFM) are two rare genetic conditions. Here we report a clinical entity comprising CHH and 
SHFM.
Methods—We identified patients with CHH and SHFM through international collaboration. 
Probands and available family members underwent phenotyping and screening for FGFR1 
mutations. The impact of identified mutations was assessed by sequence- and structure-based 
predictions, and/or functional assays.
Results—We identified 8 probands with CHH with (n=3, Kallmann Syndrome) or without 
anosmia (n=5) and SHFM, 7 of whom (88%) harbor FGFR1 mutations: one individual is 
homozygous for p.V429E; six individuals are heterozygous for p.G348R, p.G485R, p.Q594*, 
p.E670A, p.V688L, and p.L712P. All mutations were predicted to be loss-of-function by in silico 
analysis. Probands with FGFR1 mutations have severe GnRH deficiency (absent puberty and/or 
cryptorchidism and/or micropenis). SHFM in both hands and feet was only observed in the patient 
with the homozygous p.V429E mutation; V429 maps to the FRS2α binding domain of FGFR1, 
and functional studies of the p.V429E mutation demonstrated that it decreased recruitment and 
phosphorylation of FRS2α to FG FR 1 , thereby resulting in reduced MAPK signaling.
Conclusion—FGFR1 should be prioritized for genetic testing in patients with CHH and SHFM, 
because the likelihood of a mutation increases from 10% in the general CHH population to 88%.
Keywords
congenital hypogonadotropic hypogonadism; split hand/foot malformation; fibroblast growth 
factor receptor 1; FGF receptor substrate 2α
INTRODUCTION
Congenital hypogonadotropic hypogonadism (CHH [MIM 146110]) is a genetic disorder 
characterized by absent or incomplete pubertal development and infertility due to deficiency 
of gonadotropin-releasing hormone (GnRH) secretion or action. The co-occurrence of CHH 
with anosmia is termed Kallmann syndrome (KS [MIM 308700, 147950, 244200, 610628, 
612370, 612702]). Anosmia in KS is usually linked to agenesis of the olfactory structures, 
which provide the anatomic path for the migration of GnRH neurons from the olfactory 
placode to the hypothalamic region during embryonic development.1 To date, mutations in 
>20 genes have been found to underlie CHH, acting either alone or in combination.2
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Approximately 10-12% of CHH patients carry loss-of-function mutations in fibroblast 
growth factor receptor 1 (FGFR1), the first gene reported to be associated with both KS and 
normosmic CHH.3,4 CHH-associated FGFR1 mutations are typically heterozygous, and the 
disease is inherited as an autosomal dominant trait with variable expressivity. FGFR1 
encodes a member of the FGFR subfamily of receptor tyrosine kinases. Upon binding a FGF 
ligand in the presence of heparan sulfate, FGFR1 dimerizes and its kinase domains are 
autophosphorylated. In turn, this activates intracellular pathways that culminate in diverse 
biological responses; activation of the phospholipase C gamma (PLCγ) pathway requires 
phosphorylation of FGFR1 tyrosine 766 (Y766), while activation of the Ras-MAPK and 
PI3-K pathways is mediated by recruitment of FGF receptor substrate 2α (FRS2α).5 FGFR1 
is expressed in multiple tissues, including the brain and skeleton,6 among other functions, it 
is required for fate specification of GnRH neurons in the olfactory placode, as well as for 
GnRH neuron proliferation and migration to the hypothalamus.7 Alternative splicing of 
extracellular region-encoding exons of FGFR1 gives rise to the FGFR1b and FGFR1c 
isoforms; to date, the majority of CHH-associated mutations implicate FGFR1c as the major 
isoform relevant to GnRH neuron biology.3,4
CHH patients with loss-of-function FGFR1 mutations are enriched for additional skeletal 
phenotypes, such as cleft lip/palate, dental agenesis, mandibular hypoplasia, scoliosis, 
butterfly vertebrae, syndactyly, oligodactyly and clinodactyly.8,9 Recently, FGFR1 mutations 
(predicted to be loss-of-function) have been identified in patients with Hartsfield syndrome 
(MIM 615465),10 a rare disorder characterized by the association of holoprosencephaly, and 
split hand/foot malformation (SHFM, also called ectrodactyly), a severe malformation of the 
skeletal development with an absent or incomplete development of the central rays of hands, 
feet, or both.11 Notably, associated phenotypes including midline defect, multiple pituitary 
hormone deficiency and/or agenesis of the olfactory bulbs/tracts have been described in 
Hartsfield Syndrome patients.10,12 Herein, we report the association of CHH with SHFM, 
and show that the large majority of these SHFM-CHH patients carry loss-of-function 
FGFR1 mutations.
PATIENTS & METHODS
Patients
Via international collaboration (France, UK, Finland and United States), we identified 8 
CHH patients with SHFM (7 males and 1 female). Diagnostic criteria for CHH included: (i) 
failure to initiate and/or complete spontaneous puberty by age 18 years; (ii) serum 
testosterone ≤3 nmol/L for men or estradiol ≤0.07 nmol/L for women, with low or normal 
levels of serum gonadotropins; (iii) otherwise normal pituitary function (absence of clinical 
and/or biochemical evidence of TSH, ACTH, GH deficiency, hyperprolactinemia, or 
diabetes insipidus), and (iv) normal magnetic resonance imaging (MRI) of the 
hypothalamic-pituitary region; or, in infants, (v) micropenis and/or cryptorchidism in the 
setting of low sex steroid and gonadotropin levels during the “mini-puberty”. 13 Assessment 
for spontaneous partial pubertal development was made based on clinical history, Tanner 
stage, and (in males) testicular size. Olfaction was assessed by self-report and/or formal 
smell testing (brief smell identification test, B-SIT or olfactometry). Skeletal phenotypes 
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assessed included SHFM, cleft lip/palate, and dental agenesis. The institutional review 
board/ethics committee of the Massachusetts General Hospital, Hôpital Robert Debré, 
Helsinki University Central Hospital, and University College London Medical School 
approved the studies; all subjects or parents/legal guardians provided written informed 
consent.
Sequencing
Genomic DNA was obtained from peripheral blood samples using standard phenol-
chloroform extraction. Mutation screening for FGFR1 (NM_023110.2) was performed as 
previously described.2 The coding exonic and proximal intronic (≥15 bp from splice sites) 
DNA sequences of FGFR1 were amplified by PCR and analyzed by direct sequencing. 
Sequence variations were found on both DNA strands and were confirmed in a separate 
PCR. Variants were considered pathogenic mutations if: (i) their allele frequency was <1% 
in the 1000 Genomes dataset and in Exome Variant Server (EVS), and (ii) the altered amino 
acid was predicted to be loss-of-function by structural modeling14 or by at least two 
prediction programs: PolyPhen-215, SIFT16, PMut17, Mutation Taster18 and Condel 19 for 
missense variants. All subjects were also screened for the presence of mutations in FGF8 
(MIM 600483). Other CHH genes were selectively sequenced in some subjects 
(Supplementary data): KAL1 (MIM 300836), PROKR2 (MIM 607123), PROK2 (MIM 
607002), TACR3 (MIM 162332), TAC3 (MIM 162330), GNRHR (MIM 138850), GNRH1 
(MIM 152760), KISS1R (MIM 604161), KISS1 (MIM 603286), NSMF (MIM 60813), 
CHD7 (MIM 608892), and HS6ST1 (MIM 604846) (primers and PCR conditions are 
available upon request).
Structural modeling
To predict the functional consequences of the identified FGFR1 mutations, the following 
structures were used: (i) crystal structure of the extracellular ligand-binding domain of 
human FGFR1 in complex with human FGF2 (PDB ID: 1FQ9);20 (ii) crystal structure of the 
phosphorylated tyrosine kinase domain of human FGFR1 (PDB ID 3GQI);21 and (iii) 
nuclear magnetic resonance (NMR) solution structure of a 22 residue-long peptide derived 
from the juxtamembrane region of FGFR1 (residues 409-430) in complex with the FRS2α 
phosphotyrosine binding (PTB) domain (PDB ID: 1XR0).22 The structures were analyzed 
using program O and structural representations were prepared using PyMol.
Analysis of recruitment and phosphorylation of FRS2α by FGFR
Cell-based FRS2 phosphorylation assay—We first evaluated the effect of the V429E 
mutation on the ability of FGFR1c to phosphorylate FRS2 using cell-based assay. WT and 
V429E FGFR1c were cloned into the lentiviral vector FUCRW following standard 
protocols. BaF3 cells were maintained as described23 and transfected with FGFR1 
pseudoviral stock in Hank's Balanced Salt Solution buffer. Stably transduced cells were 
treated with 1.5 nM of FGF1 for 10 min, rinsed in PBS and then lysed in RIPA buffer 
(Thermo Scientific). Cell extract (30 μg) was resolved by SDS-PAGE and analyzed by 
western blotting using anti FGFR1 (inhouse antibody raised in rabbit), anti-FRS2 (Abcam 
ab10425) and anti Phospho-FRS2-α (Tyr196) (Cell Signaling, #3864) antibodies.
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Surface plasmon resonance (SPR) assay—The preparation of FGFR2 and FRS2 
peptides and SPR spectroscopy analysis was performed following published protocol (for 
details see the supplementary materials).24
In vitro FRS2 phosphorylation assay—To study the impact of the V430E mutation on 
phosphorylation of FRS2α, FGFR2CDWT (2 μM) or FGFR2CDV430E were mixed with 
FRS2αPTB (40 μM) in a reaction buffer consisting of 25mM ATP, 50mM MgCl2 25mM 
Hepes (pH 7.5) and 150mM NaCl at ambient temperature. Reactions were quenched at 
different time points by the chelating the Mg2+ with equal moles of EDTA. Following tryptic 
digestion, the amount of a phospho-Y196-containing peptide derived from FRS2αPTB was 
quantified by Orbitrap mass spectrometry and expressed as a fraction of the total amount of 
Y196-containing tryptic peptide.
FGFR1 signaling reporter gene assays—The activation of downstream signaling 
pathways by wild type and mutated FGFR1 constructs was interrogated using two firefly 
luciferase-based reporter bioassays: the osteocalcin FGF response element (OCFRE) 
reporter, which reports activity of the MAPK pathway downstream of FRS2α signaling14 
and a Nuclear Factor of Activated T-cells (NFAT) reporter (addgene plasmid 10959),25 
which reports activity of the PLCγ /IP3/Ca2+ cascade independent of FRS2α.
26
 Transient 
transfection experiments in L6 myoblasts and luciferase assays were performed as 
previously described.14 Each experiment was performed in triplicate and repeated ≥3 times. 
The data were fitted with three-parameter sigmoidal curves using Prism5 (GraphPad 
Software Inc., San Diego, CA) and the dose-response curves of mutant receptors were 
compared to that of wild type FGFR1 using the Prism5 F-test function.
FGFR1 protein abundance, maturation, and cell surface expression assays—
The FGFR1 V429E mutation was subcloned into the previously described FGFR1c 
expression construct myc-FGFR1WT, which incorporates a N-terminal myc-tag for 
antibody-mediated detection.14 The impact of the mutation on the total abundance, folding, 
and cell surface expression of the receptor were assayed in COS-7 cells as previously 
described;14 results of 3 experiments each performed in quadruplicate were compared by 
Mann-Whitney test.
RESULTS
Loss-of-function FGFR1 mutations are highly prevalent in patients with CHH and SHFM
We identified 8 CHH probands (7 males and 1 female) with SHFM, including 3 KS patients 
(Table 1, Supplementary data). Seven mutations in FGFR1 were identified in 7 male CHH 
probands (Table 1, Figure 1); thus 88% of CHH patients with SHFM harbor mutations in 
FGFR1. Among the probands with FGFR1 mutations, 4 also exhibit cleft palate; five cases 
are clearly familial (families 1-4, 7, Figure 1). The proband exhibiting the most severe 
SHFM phenotype (both hands and feet affected, with additional syndactylies) carries the 
homozygous missense mutation p.V429E.27 In contrast, 6 probands with SHFM (limited to 
either one foot or both feet) carry heterozygous mutations, 5 missense and one nonsense: 
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p.G348R, p.G485R, p.Q594*, p.E670A, p.V688L, p.L712P (Table 1). Two mutations 
(p.G348R and p.E670A) have been previously reported 2829
Previously reported mutations identified in CHH patients are distributed evenly between the 
extracellular and intracellular domains (Figure 2A). In contrast, the majority of the FGFR1 
mutations (5/7) in the probands with CHH and SHFM affect amino acids located in the 
tyrosine kinase domain (Figure 2B). The nonsense mutation (p.Q594*) is expected to lead to 
synthesis of a truncated inactive receptor that lacks the part of the tyrosine kinase domain 
containing the catalytic site. For missense mutations, the affected residues are conserved 
across vertebrates (Figure 2B), and all mutations are predicted to be loss-of-function (Table 
S1, Figure S1, Supplementary data). p.E670A has been shown to impair FGFR1 downstream 
signaling as assessed by an in-vitro MAPK phosphorylation assay.29 p.V429E is the first 
reported mutation within the domain of FGFR1 that binds FRS2α, the docking protein that 
mediates MAPK pathway activation30 (Figure 3A, Supplementary data).
The FGFR1 -V429E substitution abolishes recruitment and phosphorylation of FRS2α by 
the FGF receptor
We chose to functionally verify our structural predictions on the p.V429E substitution as this 
is the first report of a mutation that would selectively impact a specific signaling pathway 
downstream of FGFR. A lentiviral expression system was used to express the wild type 
FGFR1c and its V429E variant in BaF3 cells, which lack endogenous FGFR expression. 
Cells were transfected with the wild type FGFR1c or the V429E FGFR1c mutant constructs, 
treated with FGF1, and FRS2α phosphorylation on tyrosine 196, one of the major Grb2 
binding site of FRS2α , was assessed by western blotting with phosphospecific anitobodies. 
As shown in Figure 3B, wild type FGFR1c phosphorylated FRS2α on tyrosine 196 whereas 
the V429E mutant did not. For in vitro binding and phosphorylation experiments, we used 
the FGFR2 intracellular domain. This was necessary because the expression level of FGFR1 
intracellular domain in E.coli is too low to allow for carrying out these experiments. In 
contrast, FGFR2 intracellular domain can be expressed abundantly and can be purified to 
high homogeneity using E.coli expression system. This approach was legitimate because 
FGFR1 and FGFR2 are structurally and functionally highly homologous. The FRS2α 
binding sites are highly conserved between these FGFRs and alternative splicing in both 
FGFRs, and the exclusion of the conserved Val-Thr motif eliminates FRS2α recruitm ent to 
the FG FR .31 Wild type FGFR2 intracellular domain (residues 401-821; FGFR2CDWT), the 
corresponding mutated fragment (FGFR2CDV430E), and the PTB domain of FRS2α 
(residues 11-140; FRS2αPTB) were expressed in E.coli as His-tagged proteins and purified 
to homogeneity. FRS2α was immobilized onto a CM5 chip sensor over and increasing 
concentrations of FGFR2CDWT or FGFR2CDV430E were flowed over the sensor chip. 
FGFR2CDWT bound FRS2αP with a KD of 320 nM, whereas the FGFR2CDV430E mutant 
failed to bind to FRS2αPTB (Figure 3C). We also examined the effect of the mutation on the 
ability of the mutant receptor to phosphorylate FRS2α using an in vitro kinase assay. Briefly, 
purified FRS2α protein was mixed with FGFR2CDWT or FGFR2CDV430E in a mole ratio of 
20:1, and supplemented with a Mg-ATP mixture to start the phosphorylation reaction. 
Phosphorylation of FRS2α on tyrosine 196 as a function of time was monitored by mass 
spectrometry and was expressed as percentage of the phosphorylated substrate. As shown in 
Villanueva et al. Page 6
Genet Med. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3D, the V430E mutation diminishes the ability of FGFR2 to phosphorylate FRS2α. 
These data demonstrate that the FGFR2-V430E substitution diminishes the ability of FGFR2 
to recruit and phosphorylate FRS2α in vitro. In contrast to cell-based data, the mutation did 
not abolish FRS2α phosphorylation in vitro. This was expected, because the high 
concentrations of FGFR kinase and FRS2α (several orders of magnitude greater than those 
in cell-based experiments) have resulted in recruitment-independent phosphorylation of 
FRS2α by the FGFR kinase. Collectively, these cell-based and in vitro data demonstrate that 
the FGFR1-V429E substitution diminishes the ability of FGFR1 to recruit and 
phosphorylate FRS2α.
The FGFR1 V429E substitution compromises FGFR1 MAPK signaling in vitro
We then studied the effects of the mutation on downstream signaling using the the OCFRE 
and NFAT reporter systems. Stimulation of wild type receptor with increasing doses of 
FGF2 resulted in a typical sigmoidal dose-response curve with ~5-fold maximal induction of 
reporter activity (Figure 3E). The V429E mutant displayed reduced inducibility: 56% of 
wild type at maximum activity (p <0.001, Figure 3E), suggesting compromised MAPK 
signaling. In contrast, V429E behaved similar to the wild type receptor in the NFAT reporter 
assay (Figure 3F), indicating normal PLCγ /IP3/Ca2+ signaling. These findings indicate that 
V429E represents a partial loss-of-function mutation that compromises the activation of 
FRS2α dependent MAPK signaling without affecting FRS2α independent PLCγ /IP3/Ca2+ 
signaling by FGFR1.
To exclude the possibility that the V429E mutation leads to loss of function by impairing 
FGFR1 receptor protein synthesis and/or maturation, we investigated whether it impacted 
FGFR1 total abundance, glycosylation, or cell surface expression. When the lysate of 
transiently transfected COS-7 cells was subjected to western blot analysis under reducing 
conditions, FGFR1 was detectable as two protein bands of 140 kDa and 120 kDa (Figure 
3G). When the lysate was pretreated with Peptide N-Glycosidase F (PNGase), which 
removes all N-linked carbohydrate chains, FGFR1 was detectable as a single band of ~100 
kDa, confirming that the two bands are differently N-glycosylated receptor pools. The total 
protein abundance was calculated as the ratios of PNGase-treated bands to ß-actin band 
densities; the value calculated for the V429E mutant was normalized to the WT receptor. 
Treatment with endoglycosidase H (Endo H), which removes only high mannose N-linked 
sugars, altered the mobility of only the 120 kDa FGFR1 band (Figure 3G), indicating that 
this pool represents the partially processed immature receptor, whereas the Endo H-resistant 
140 kDa band represents the mature form of FGFR1. Receptor “maturation index” was 
estimated by calculating the ratio of the 140 kDa band to the total FGFR1 immunoreactivity 
of EndoH-treated samples. The total abundance (mean±SEM: 1.07±0.30, p>0.05) and the 
maturation index (1.04±0.05, p>0.05) of V429E were not different from wild type, 
suggesting that the mutation did not compromise receptor synthesis or maturation. The cell 
surface abundance of V429E was slightly elevated (by 20% relative to wild type, p<0.05) 
(Figure 3H), thus excluding reduced expression as cause for decreased signaling activity. 
Hence, the V429E mutation imparted loss of receptor function by selectively inhibiting the 
ability of the receptor to interact with its major downstream substrate FRS2α and to 
transduce respective intracellular signals.
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Variable expressivity of phenotypes associated with FGFR1 mutations
In family 1, the proband with the homozygous mutation (p.V429E) exhibits severe 
reproductive, olfactory, and skeletal phenotypes (SHFM in hands and feet and syndactylies). 
The only detectable phenotype among the three heterozygous family members analyzed is 
hyposmia in the proband's sister. In family 2, the proband with KS, SHFM, and cleft lip and 
palate inherited the heterozygous mutation (p.V688L) from his affected mother who also 
exhibits KS and cleft lip and palate but not SHFM. In family 3, the proband with KS and 
SHFM inherited the heterozygous mutation (p.L712P) from his unaffected mother; his two 
sons (III-1 and III-2), who carry the mutation both have syndactyly and one has CHH. In 
family 4, the proband with CHH, SHFM, and cleft palate inherited his heterozygous 
mutation (p.G485R) from his unaffected mother. His brother, who carries the same mutation 
has CHH, was born with syndactyly and cleft palate. Finally, in family 7, the proband who 
carries the p.E670A mutation has CHH, SHFM, and cleft palate. DNA was not available 
from his parents. His affected brother with the identical FGFR1 mutation has KS and cleft 
palate. Thus, among the 5 familial cases, SHFM was found in the CHH probands and in 
three additional members in family 1 whose genotype and reproductive phenotype are 
unknown (two stillborn females and one male with neonatal death). On the other hand, 
CHH, anosmia/hyposmia, syndactyly, and cleft lip/palate were found in several family 
members carrying the FGFR1 mutation (Figure 1).
DISCUSSION
We show here that FGFR1 mutations are present in most cases of CHH with SHFM (88%). 
Several patients also exhibited anosmia (patients 1, 2, 3), cleft palate (patients 2, 4, 5, 7) or, 
more rarely, absent septum pellucidum and hypoplastic anterior corpus callosum (patient 1), 
phenotypes previously reported in association with FGFR1 mutations.3,4 FGFR1 mutations 
have been recently reported to underlie Hartsfield Syndrome, defined as the combination of 
holoprosencephaly and SHFM.10 A broad radiologic spectrum has been reported in 
holoprosencephaly, including absence of septum pellucidum and corpus callosum at the 
milder end.32 This phenotype was observed in patient 1 with CHH and SHFM. Further, 
patients with Hartsfield syndrome may have olfactory bulb agenesis and/or multiple pituitary 
hormone deficiency (including hypogonadotropic hypogonadism).10,12 Thus, our results 
show a substantial phenotypic and genetic overlap between CHH with SHFM on the one 
hand, and Hartsfield syndrome on the other. Indeed, FGFR1 is a pleiotropic gene involved 
not only in the GnRH neuron ontogeny and olfactory system development, but also 
implicated in forebrain development and embryonic limb morphogenesis. It is interesting to 
note that 7/8 probands reported here are males and 7/7 males were found to carry loss-of-
function mutations in FGFR1. The sole CHH and SHFM patient without a FGFR1 mutation 
is a female with ectrodactyly of the right hand and foot, and cleft palate. A similar male 
predominance has been observed in Hartsfield Syndrome.10
In the consanguineous family 1, the disease is apparently inherited as a recessive trait, which 
is unusual for CHH associated with FGFR1 mutations.3 The proband carries a homozygous 
p.V429E mutation while 3 family members are heterozygous for the mutation and only one 
among them exhibits hyposmia, a phenotype which can be associated with CHH. This may 
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be due to the fact that the p.V429E mutation causes only partial loss of function, such that 
two mutant alleles are needed to manifest the disease phenotype. In the other 6 families, 
FGFR1-associated CHH with SHFM was inherited as an autosomal dominant trait with 
incomplete penetrance. For example, among the informative pedigrees, the mutation was 
transmitted by unaffected mothers (families 3 and 4); additional mutation carriers without 
SHFM are present in families 2, 3, 4, and 7. However, although SHFM is classically 
described as an absence of the central ray, a broader range of limb extremity abnormalities 
has been described within this entity such as syndactyly.11 Accordingly, the apparent 
penetrance of FGFR1 mutations increases when the phenotype was considered as CHH 
associated to limb abnormality extremities and not only to SHFM (2 CHH patients and one 
prepubertal individual in families 3 and 4 harboring FGFR1 mutations exhibit syndactyly). 
Oligogenicity,2,27 and/or interaction with environmental factors33 may contribute to the 
incomplete penetrance and variable expressivity of CHH, SHFM with other limb extremity 
abnormalities and olfactory phenotypes.
Several lines of evidence support that the SHFM in these CHH probands is the consequence 
of the FGFR1 signaling defect. Fgfr1 restricts the number of cells in nascent limb buds and 
specifies digit placement and identity in developing limbs.34,35 Mice with inactivation of 
Fgfr1 in sonic hedgehog-expressing cells of developing limb buds lack the 3rd digit in all 
forelimbs and hindlimbs, which corresponds to the human SHFM phenotype.35 
Additionally, mice with inactivation of Fgfr1 in limb mesenchyme immediately after limb 
bud initiation exhibit fused/missing 1st and 2nd digits similar to the phenotype of patients 1, 
5 and 6.34 These data are consistent with a critical role for FGFR1 in limb development and 
SHFM pathogenesis. To date, the only gene associated with isolated (non-syndromic) SHFM 
in both mice and humans is TP63.36 Interestingly, the limb buds of Tp63−/− mice have 
markedly decreased expression of Fgf8 in the apical ectodermal ridge (AER) of limb buds;37 
Fgf8 is required for proliferation of the underlying mesenchymal cells. Moreover, mice with 
double conditional knock out of Fgf8 and Fgf4 in AER cells exhibit aplasia of both proximal 
and distal limbs.38 Lastly, a locus for SHFM maps to a region that includes FGF8 
(chromosome 10q24-q25).39 FGF8 is a potent ligand for FGFR1, and both FGF8 and 
FGFR1 loss-of-function mutations underlie CHH through defects in olfactory bulb or GnRH 
neuron development.40 Mutations in FGF8 are a rare cause of CHH (~1%), and none were 
found in the 8 CHH-SHFM probands reported here.
The most severe limb extremity phenotype, with median clefts in both hands and both feet as 
well as multiple syndactylies, was observed in the patient with a homozygous FGFR1 
mutation (p.V429E). The p.V429E mutation is the first one identified in the binding domain 
for FRS2α; structural and functional studies show that the mutation selectively abolishes the 
interaction of the receptor with FRS2α, an adaptor critical for activation of the MAPK and 
PI3-K cascades.5 MAPK activation by FGF signaling is known to promote survival and 
neurite outgrowth in GnRH neurons.7 The p.V429E mutation suggests a role for FRS2α-
mediated FGFR1 signaling not only for GnRH neuron ontogeny, but also for distal limb 
development in humans. The remaining 6 patients with heterozygous FGFR1 mutations 
exhibit milder SHFM phenotypes with a median cleft in either one foot (n=2) or both feet 
(n=4).
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In conclusion, the association of CHH with SHFM is a clinical entity with a high frequency 
of FGFR1 mutations. A main limitation of this study is that it was not designed to assess the 
percentage of the general CHH population that presents SHFM; rather, the cases were 
assembled based on phenotypes that had come to the attention of the many collaborating 
physicians. To address the exact prevalence of CHH with SHFM, systematic phenotyping of 
defined CHH cohorts is necessary; which is beyond the scope of this study. Nevertheless, 
our findings have implications for clinic practice: Firstly, the high frequency of FGFR1 
mutations in patients with CHH and SHFM compared to the general CHH population 
suggests that FGFR1 should be prioritized for genetic screening in CHH patients with 
SHFM. Secondly, as diagnosis of CHH in infancy can facilitate early treatment with 
gonadotropins/GnRH to promote both gonadal development and future fertility in 
adulthood,13 we propose that neonates with SHFM be assessed for CHH through evaluation 
at birth for micropenis and cryptorchidism in males; hormonal testing during the 
“minipuberty”; MRI of olfactory structures; and/or genetic screening of FGFR1. Lastly, 
further refining the clinical and genetic overlap between CHH, SHFM and Hartsfield 
syndrome is expected to facilitate a better understanding of their pathologic mechanisms, 
and to elaborate a rational algorithm for genetic diagnosis.
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Figure 1. FGFR1 mutations underlie CHH with SHFM
(A) Pedigrees of the 7 CHH and SHFM families with FGFR1 mutations; probands are 
denoted by arrows, SB: stillborn, OB: olfactory bulbs. A: homozygous mutation.
(B) Photographs and radiographs demonstrating severe skeletal anomalies of hands and feet 
among probands.
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Figure 2. FGFR1 mutations identified in probands with CHH and SHFM
(A) Schematic of FGFR1 showing the locations of all published FGFR1 mutations 
associated with CHH (Kallmann syndrome or normosmic CHH, red circles), Hartsfield 
syndrome (blue squares), septo-optic-dysplasia (green triangles). SP: signal peptide, D1: 
immunoglobulin domain 1, AB: acid box domain, D2: immunoglobulin domain 2, D3: 
immunoglobulin domain 3, TM: transmembrane domain, F: FRS2α -binding domain, TKD: 
tyrosine kinase domain, stars: mutations described in this study.
(B) FGFR1 mutations identified in probands with CHH and SHFM, all the substituted 
residues of missense mutations are conserved across vertebrates (cow, mouse, chicken, 
xenopus, and zebrafish) and in human FGFR2 (hFGFR2).
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Figure 3. The V429E substitution in FGFR1 impedes recruitment and phosphorylation of FRS2α 
and FGF2-induced MAPK signaling
(A) Analysis of the impact of the V429E mutation based on the NMR structure of the FRS2 
phosphotyrosine binding (PTB) domain in complex with the juxtamembrane (JM) region 
peptide of FGFR1. The FRS2 PTB domain and FGFR1 JM peptide are shown as purple and 
green ribbons respectively, and side chains of the V429 of FGFR1 and L62, M105, V112 of 
FRS2 are rendered in sticks. The molecular surfaces of L62, M105, and V112 of FRS2 PTB 
are also shown, to highlight their hydrophobic contacts with V429 of FGFR1.
(B) The V429E FGFR1c mutant fails to phosphorylate FRS2 in cell based assay. BaF3 were 
transfected with lentiviral vectors expressing WT or V429E FGFR1c and FRS2 
phosphorylation was assessed upon FGF1 treatment by western blotting using anti phospho-
FRS2-α specific antibodies . WT: wild type; EV: empty vector.
(C) Analysis of the impact of the V429E mutation on the ability of FGFR1 to recruit 
FRS2α . The assay was based on FGFR2 V430E, which is equivalent to FGFR1 V429E. 
Increasing concentrations of FGFR2CDWT and FGFR2CDV430E (carrying the equivalent 
mutation to FGFR1-V429E) ranging from 12.5 to 400 nM were passed over a CM5 chip 
onto which FRS2α had been immobilized. As representative of the full dataset, binding 
responses obtained for injections of 200 nM of FGFR2CDWT or FGFR2CDV430E are shown. 
The rising and falling parts of the wild type curve (blue) represent the association and 
dissociation phases, respectively, of FGFR2CDWT-FRS2α binding over time. At 200 nM, 
FGFR2CDWT exhibits maximal binding of 55 response units (blue), whereas 
FGFR2CDV430E shows negligible binding (red). According to a steady-state equilibrium 
analysis of the full data sets (not shown), FGFR2CDWT binds FRS2α with a KD of 320 nM, 
whereas the FGFR2CDV430E negligible binding to FRS2α.
(D) The V429E mutation reduces the ability of FGFR1 to phosphorylate FRS2 on Y196 in 
vitro. FGFR2WT and FGFR2V430E mutant kinases were allowed to phosphorylate FRS2 
fragment PTB9-200 on Y196, a tyrosine phosphorylation site known to be required for Grb2 
recruitment, at room temperature for 0, 1, 3, 5 10, 15, 20, 25, 30 minutes. Following tryptic 
digestion, samples were analyzed by Orbitrap mass spectrometry to quantify the phospho-
Y196-containing tryptic peptide. FGFR2WT is shown in blue and FGFR2V430E is shown in 
red.
(E-F) The V429E mutation is loss-of-function in the OCFRE reporter assay (FRS2α 
dependent MAPK signaling) and not different from WT in the NFAT reporter assay (FRS2α 
independent PLCγ /IP3/Ca2+ signaling). Data shown represent the means ± S.E.M. of 3 
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experiments. FGFR1 WT is shown in blue, FGFR1V429E in red, empty vector in black. 
Relative to the maximal stimulation of WT (%), ** p<0.001, NS: not significant.
(G) Total abundance and maturation of recombinant FGFR1 proteins. COS-7 cells were 
transfected with FGFR1 constructs and the cell lysates were subjected to deglycosylation 
treatment followed by western blot analysis. PNGase-treated bands represent total protein 
abundance levels; 140kDa Endo H-treated bands represent the mature form while 100kDa 
Endo H-treated bands represent immature form of FGFR1. The experiment was performed 
three times, tested by Mann-Whitney test for statistic significance, no significant difference 
in overall expression and maturation index between WT and V429E. PNGase: Peptide N-
Glycosidase F-treated; Endo H: endoglycosidase H-treated; WT: wild type; EV: empty 
vector.
(H) Cell surface abundance of the transiently transfected FGFR1 mutant in COS-7 cells. 
Cell surface abundance levels were measured by a radiolabeled antibody binding assay and 
plotted as a percentage of wild type levels. The abundance level of cell surface expressed 
FGFR1V429E was significantly higher than FGFR1wt. Values shown are the means ± SEM of 
3 experiments each performed in quadruplicate. The difference between the mutant and the 
wild type receptor expression was compared by Mann-Whitney test, * p<0.05.
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